Merck Group Reports Q2 2026 Profit Decline, Raises Full-Year Guidance

Merck Group’s Q2 2026 earnings, released on August 8, revealed a sharper profit decline than analysts had expected, ye...

Read story →

Merck Secures First Oral PCSK9 Inhibitor, Boosts Q1 2026 Earnings and Expands Oncology Pipeline

Merck’s latest triumph—an FDA nod for its first oral PCSK9 inhibitor—comes on the heels of a stronger‑than‑exp...

Read story →